Key points

In infants

• The mandatory meningococcal ACWY vaccination program implemented on January 1, 2025, for infants, following an increase in cases of invasive meningococcal infections of types W and Y, has resulted in high vaccination coverage, with 87% of infants born in 2025 having received the first dose of the ACWY meningococcal vaccine—a coverage rate close to the national level (2 percentage points lower).
• Among children born in 2024—that is, before the replacement of the meningococcal C vaccine with the ACWY vaccine—75% had received at least one dose of the tetravalent ACWY meningococcal vaccine by the age of 21 months. This vaccination coverage was lower than that estimated in 2024 for meningococcal C and also lower than the national level (-5 percentage points). It should be noted that vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year the mandatory vaccination against meningococcal B was implemented for infants up to 2 years of age, vaccination coverage against these infections has increased significantly, with 58% of infants born in 2024 (aged 21 months) up to date with their vaccinations (compared to 42% in 2024, an increase of 16 percentage points). This coverage was nevertheless 8 percentage points lower than the national rate.
• Vaccination coverage for other mandatory infant vaccinations is
  generally high but below 90% and thus below the 95% target set by
  the World Health Organization (WHO).
• Given the resurgence of measles virus circulation in France since 2024, it is important to note that vaccination coverage for the two-dose MMR vaccine must exceed this target to interrupt the circulation of the virus, which can lead to deaths among vulnerable individuals. Verifying and updating this vaccination status is essential for both children and young adults.

In adolescents and young adults

• Given the potential severity and increased frequency of invasive meningococcal infections during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 10% of 11- to 14-year-olds and 3% of 15- to 24-year-olds had received a dose of this vaccine. These coverage rates were lower than those observed at the national level. Meningococcal ACWY vaccination must be intensified in this age group.
• Incorporating this vaccination into campaigns conducted in middle schools starting in 2026 will help strengthen young people’s protection against these infections. Efforts to improve meningococcal coverage in other age groups. Vaccination
  coverage against human papillomavirus (HPV) infections continues to increase, with 43% of 16-year-old girls and 20% of 16-year-old boys having completed the full vaccination series. These coverage rates were about 10 percentage points lower than the national average.
• The gap in vaccination coverage between girls and boys continues to narrow.
  This progress is encouraging, but vaccination coverage remains insufficient to reduce the incidence of cancers linked to these infections. Efforts must therefore continue to achieve the national vaccination coverage target set by the 10-year cancer control strategy of 80% for girls and boys by 2030, by building on vaccination campaigns in middle schools and reinforcing messages about the importance of vaccinating boys.

Vaccine Acceptance

According to the 2024 Santé publique France Barometer in Corsica, 76% of young people aged 18 to 25 said they were in favor of vaccination in general.